Cutibacterium acnes Infections: Diagnosis and Management

Introduction to C. acnes

The American Academy of Dermatology notes that C. acnes is most recognized for its role in acne vulgaris 1

The Infectious Diseases Society of America recommends that C. acnes infections be diagnosed through deep tissue biopsy and prolonged anaerobic culture (up to 14 days) for detection, as swab cultures have low sensitivity and high contamination risk 2
The Centers for Disease Control and Prevention suggest that the consensus definition for fracture-related infection requires at least two separate deep tissue specimens with identical pathogens to confirm infection 2

The American College of Allergy, Asthma, and Immunology states that more likely pathogens for a non-healing intranasal septal lesion include Staphylococcus aureus (including MRSA) 3, Streptococcal species 4, Gram-negative organisms 3, fungal infections (Aspergillus, mucormycosis) 3, and mycobacterial infections 5

The Clinical Microbiology and Infection society recommends that if C. acnes is confirmed as the causative organism, treatment should involve antibiotics such as beta-lactams, clindamycin, doxycycline/tetracyclines, and rifampicin, with a treatment duration of 3 months total antibiotic therapy for implant-associated C. acnes infections 6
The Pediatric Infectious Diseases Society suggests that empiric antibiotics should cover S. aureus (including MRSA), streptococci, and potentially gram-negatives, but not C. acnes 7

The Clinical Microbiology and Infection society advises against treating C. acnes based on a single superficial swab culture, as this almost certainly represents contamination 2
The Infectious Diseases Society of America recommends avoiding starting antibiotics before obtaining proper cultures, unless the patient is hemodynamically unstable 5

The Clinical Microbiology and Infection society recommends clindamycin for C. acnes infections due to its biofilm activity 8
The Clinical Microbiology and Infection society suggests beta-lactams, such as amoxicillin or penicillin, are effective but lack biofilm activity 8
Recent evidence supports switching to oral antibiotics at day 7 as non-inferior to 6 weeks IV therapy, with lower complication rates, according to the Clinical Microbiology and Infection society 8

For early infection (within 3 months post-op), debridement with implant retention (DAIR) may be considered, combined with appropriate antibiotic therapy, as recommended by the Clinical Microbiology and Infection society 8

Rifampicin must always be combined with a second agent to prevent resistance emergence, as stated by the Clinical Microbiology and Infection society 8
Rifampicin has demonstrated biofilm activity in vitro and animal models, according to the Clinical Microbiology and Infection society 8